New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:43 EDTOHRPOhr Pharmaceutical weakness a buying opportunity, says Brean Capital
Brean Capital said the weakness in Ohr Pharmaceutical due to investors concerns surrounding insufficient dosing for its AMD trials should be used as a buying opportunity. The firm believes the concerns are overblown and that short sellers and a weak biotech sector are driving the price lower. Shares remain Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:00 EDTOHRPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTOHRPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amira Nature Foods (ANFI), up 8.6%... Stratasys (SSYS), up 3.6%... Magnum Hunter (MHR), up 3%. ALSO HIGHER: Mavenir Systems (MVNR), up 19.1% after Mitel (MITL) agrees to acquire Mavenir Systems for $560M... Athersys (ATHX), up 19.7% following license agreement and collaboration with Chugai... OHR Pharmaceutical (OHRP), up 11.4% following additional positive data from OHR-102 IMPACT study... NXP Semiconductors (NXPI), up 14% following merger agreement with Freescale Semiconductor (FSL). Freescale Semiconductor is up 9.1%... Mast Therapeutics (MSTX), up 7.7% following positive results from Vepoloxamer study. DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.7%... Scorpio Tankers (STNG), down 4.5%. ALSO LOWER: Lumber Liquidators (LL), down 24.2% following CBS' 60 Minutes says that the company is linked to health and safety violations... Aruba Networks (ARUN), down 1.7% after HP (HPQ) confirms deal to acquire Aruba Networks for $24.67... Pacira Pharmaceuticals (PCRX), down 14.4% after receiving complete response letter from FDA for sNDA in use of Exparel... 500.com (WBAI), down 14.4% after announcing that temporary suspension will adversely impact financial results.
07:59 EDTOHRPOhr Pharmaceutical announces additional positive data from OHR-102 IMPACT study
Subscribe for More Information
07:47 EDTOHRPOhr Pharmaceutical initiated with an Outperform at Cowen
Subscribe for More Information
February 26, 2015
08:19 EDTOHRPOhr Pharmaceutical appoints Avner Ingerman, M.D. as Chief Clinical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use